Company Overview
Accendra Health, Inc. operates as a healthcare solutions provider in the United States, offering a comprehensive range of products and services designed for in-home care and delivery for diabetes treatment, as well as home respiratory therapy including home oxygen and non-invasive ventilation services. The company functions within the broader Healthcare sector, specifically under the Medical Distribution industry, positioning it as a specialized distributor of essential medical equipment and therapeutic solutions to various care providers. At a significant scale, Accendra Health holds a market capitalization of $158.22 million and generates annual revenue of $2.76 billion, supported by an employee base of 6,500 individuals. These financial metrics indicate a substantial operational footprint, suggesting that while the company commands a notable market cap relative to its current valuation, the revenue figure reflects a large-scale distribution network capable of serving a wide geographic area within the domestic healthcare landscape.
Financial Health
The company reported a total revenue of $2.76 billion over the trailing twelve months, yet recorded a net income of -$102,682,000, while generating an EBITDA of $360.74 million. The substantial disparity between the $2.76 billion in revenue and the negative net income reveals a cost structure where operating expenses, likely driven by high volume of goods distributed and service delivery costs, significantly erode bottom-line profitability despite strong earnings before interest, taxes, depreciation, and amortization. Despite the reported net loss, the entity generated free cash flow of $671.68 million, which indicates a high degree of financial flexibility to fund operations, invest in assets, or manage liquidity without relying solely on external financing. The company's margins reflect this complex financial picture, with a gross margin of 46.7% indicating healthy pricing power or cost control on sales, an operating margin of 2.9% showing moderate efficiency after overheads, and a profit margin of -39.8% highlighting the severe pressure on net profitability. On the balance sheet, Accendra Health holds cash of $281.99 million against total debt of $2.16 billion, with a debt-to-equity ratio listed as N/A, suggesting a highly leveraged position where liabilities substantially outweigh equity. This leverage is further contextualized by a current ratio of 0.58, which indicates that the company's current assets are insufficient to cover its current liabilities, pointing to potential short-term liquidity constraints. Additionally, the return on equity stands at -163.8% and the return on assets is 2.6%, metrics that reveal management effectiveness is currently challenged by the net loss, yet the positive ROA suggests assets are still generating some level of earnings before financing costs and taxes.
Valuation Assessment
The valuation metrics present a unique picture for Accendra Health, with a trailing P/E ratio of N/A due to negative earnings and a forward P/E of 1.96, which implies that the market expects a significant turnaround in earnings trajectory to realize positive returns in the upcoming fiscal periods. The price-to-book ratio is recorded at -0.34, indicating that the company's market value is below its book value, a situation often seen in distressed or turnaround scenarios where the market price does not reflect the underlying asset value. Alternative valuation metrics such as a price-to-sales ratio of 0.06 and an EV/EBITDA of 5.65 suggest that the market is pricing the stock based on sales multiples rather than profitability, while the low EV/EBITDA multiple relative to historical standards might indicate a discount applied to the firm's earnings power. Regarding trading range, the stock has a 52-week high of $9.80 and a 52-week low of $1.84, meaning the current price sits significantly below the high, reflecting the market's current sentiment toward the company's earnings volatility. The stock exhibits a beta of 1.29, which signifies that the share price is 29% more volatile than the broader market, suggesting that investors should expect larger swings in price relative to general market movements.
Growth & Income
Accendra Health is experiencing a contraction in sales, with revenue growth year-over-year at -73.7%, while earnings growth is listed as N/A due to the negative net income position. The absence of positive earnings growth relative to the sharp decline in revenue implies that the company is facing structural challenges or a significant shift in its business model rather than a temporary slowdown. As a non-dividend payer, the company offers a dividend yield of N/A and a payout ratio of 0.0%, meaning that instead of distributing cash to shareholders, the firm retains all earnings—or in this case, absorbs losses—to potentially fund operational restructuring or debt obligations. The overall growth and income profile is characterized by a severe revenue contraction and a lack of dividend income, reflecting a period of financial distress where the primary focus is likely on preserving liquidity and stabilizing operations rather than delivering shareholder returns through growth or income.